RBX2660 Shows Promise in Breaking the Cycle of Recurrent C diff

Building on the success seen with fecal microbiota transplantation, this experimental treatment lowered the rates of recurrent C difficile infections.

Related Keywords

Minnesota ,United States ,New York ,Mayo Clinic In Rochester ,Sahil Khanna ,Lisa Malter ,American College Of Gastroenterology ,Outstanding Research Award ,Langone Health ,Drug Administration Vaccines ,Ferring Pharmaceuticals ,Advisory Committee Nod ,Products Advisory Committee ,Mayo Clinic ,Medscape Medical ,American College ,Scientific Meeting ,Research Award ,Drug Administration ,Related Biological Products Advisory Committee ,C Diff Infection ,Clostridium Difficile Infection ,Lostridium Difficile Associated Disease ,C Diff Associated Disease ,Crohns Disease ,Diarrhea ,Ulcerative Colitis ,Irritable Bowel Syndrome Ibs ,Irritable Bowel Syndrome ,Jobs ,Infectious Disease Diagnostics ,Iagnostics Infectious Disease ,Abdominal Pain ,Inflammatory Bowel Disease ,Nflammatory Bowel Disease Ibd ,Bd ,Pain Management ,Ai ,